New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
Identifieur interne : 004D86 ( Main/Exploration ); précédent : 004D85; suivant : 004D87New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
Auteurs : John S. Oxford [Royaume-Uni] ; Shobana Balasingam [Royaume-Uni] ; Charlotte Chan [Royaume-Uni] ; Andrew Catchpole [Royaume-Uni] ; Robert Lambkin [Royaume-Uni]Source :
- Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (usage thérapeutique), Asie, Cellules Vero, Chats, Humains, Phylogénie, Rats, Ribavirine (usage thérapeutique), Santé publique, Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (usage thérapeutique), Virus du SRAS (), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Vaccins antiviraux.
- pathogénicité : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Ribavirine, Vaccins antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- Wicri :
- topic : Médicament, Vaccin, Santé publique.
English descriptors
- KwdEn :
- Animals, Antiviral, Antiviral Agents (therapeutic use), Asia, Cats, Chlorocebus aethiops, Drug, Humans, Immunoprophylaxis, Phylogeny, Prevention, Public Health, Public health, Rats, Review, Ribavirin (therapeutic use), SARS Virus (classification), SARS Virus (drug effects), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Vaccine, Vero Cells, Viral Vaccines (immunology), Viral Vaccines (therapeutic use).
- MESH :
- chemical , immunology : Viral Vaccines.
- chemical , therapeutic use : Antiviral Agents, Ribavirin, Viral Vaccines.
- geographic : Asia.
- classification : SARS Virus.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Cats, Chlorocebus aethiops, Humans, Phylogeny, Public Health, Rats, Vero Cells.
Abstract
Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R0 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000684
- to stream PascalFrancis, to step Curation: 000306
- to stream PascalFrancis, to step Checkpoint: 000604
- to stream Main, to step Merge: 005124
- to stream PubMed, to step Corpus: 002868
- to stream PubMed, to step Curation: 002868
- to stream PubMed, to step Checkpoint: 002604
- to stream Ncbi, to step Merge: 000E04
- to stream Ncbi, to step Curation: 000E04
- to stream Ncbi, to step Checkpoint: 000E04
- to stream Main, to step Merge: 004A14
- to stream Main, to step Curation: 004D86
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title><author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0232555</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0232555 INIST</idno><idno type="RBID">Pascal:05-0232555</idno><idno type="wicri:Area/PascalFrancis/Corpus">000684</idno><idno type="wicri:Area/PascalFrancis/Curation">000306</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000604</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000604</idno><idno type="wicri:doubleKey">0956-3202:2005:Oxford J:new:antiviral:drugs</idno><idno type="wicri:Area/Main/Merge">005124</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15739618</idno><idno type="wicri:Area/PubMed/Corpus">002868</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002868</idno><idno type="wicri:Area/PubMed/Curation">002868</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002868</idno><idno type="wicri:Area/PubMed/Checkpoint">002604</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002604</idno><idno type="wicri:Area/Ncbi/Merge">000E04</idno><idno type="wicri:Area/Ncbi/Curation">000E04</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E04</idno><idno type="wicri:doubleKey">0956-3202:2005:Oxford J:new:antiviral:drugs</idno><idno type="wicri:Area/Main/Merge">004A14</idno><idno type="wicri:Area/Main/Curation">004D86</idno><idno type="wicri:Area/Main/Exploration">004D86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title><author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Antiviral chemistry & chemotherapy</title><title level="j" type="abbreviated">Antivir. chem. chemother.</title><idno type="ISSN">0956-3202</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral chemistry & chemotherapy</title><title level="j" type="abbreviated">Antivir. chem. chemother.</title><idno type="ISSN">0956-3202</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral</term><term>Antiviral Agents (therapeutic use)</term><term>Asia</term><term>Cats</term><term>Chlorocebus aethiops</term><term>Drug</term><term>Humans</term><term>Immunoprophylaxis</term><term>Phylogeny</term><term>Prevention</term><term>Public Health</term><term>Public health</term><term>Rats</term><term>Review</term><term>Ribavirin (therapeutic use)</term><term>SARS Virus (classification)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Structure activity relation</term><term>Vaccine</term><term>Vero Cells</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Asie</term><term>Cellules Vero</term><term>Chats</term><term>Humains</term><term>Phylogénie</term><term>Rats</term><term>Ribavirine (usage thérapeutique)</term><term>Santé publique</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Asia</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Ribavirine</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cats</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Phylogeny</term><term>Public Health</term><term>Rats</term><term>Vero Cells</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Antiviral</term><term>Asie</term><term>Cellules Vero</term><term>Chats</term><term>Humains</term><term>Médicament</term><term>Phylogénie</term><term>Rats</term><term>Santé publique</term><term>Vaccin</term><term>Prévention</term><term>Immunoprophylaxie</term><term>Santé publique</term><term>Virus du SRAS</term><term>Virus syndrome respiratoire aigu sévère</term><term>Relation structure activité</term><term>Syndrome respiratoire aigu sévère</term><term>Article synthèse</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term><term>Vaccin</term><term>Santé publique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub> value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name></region><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:05-0232555
|texte= New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |